MINNEAPOLIS, December 03, 2024--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic ...
Factors portending the greatest risk for cardiovascular death in control patients were inflammation (baseline plasma high-sensitivity C-reactive protein =2 mg/L; p=0.003) and ischemic HFrEF etiology ...
It has now been 25 years since prourokinase was in the spotlight as a potential treatment for acute ischaemic stroke. In 1999, the PROACT-II randomised controlled trial compared intra-arterial ...
New research shows that cryoablation is a safe and effective approach to close congenital patent foramen ovale (PFO, a small hole in the heart) in patients with atrial fibrillation (AF) undergoing ...